Display Settings:

Format

Send to:

Choose Destination
    Clin Pharmacol Ther. 2010 Sep;88(3):335-8. Epub 2010 Jul 21.

    The effect of donepezil treatment on cardiovascular mortality.

    Source

    Department of Medicine, Division of Clinical Pharmacology, Autonomic Dysfunction Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

    Erratum in

    • Clin Pharmacol Ther. 2010 Nov;88(5):725.

    Abstract

    The acetylcholinesterase inhibitor donepezil hydrochloride improves cognitive function in patients with Alzheimer's disease and vascular dementia. Given acetylcholine's important actions on the heart, we undertook a retrospective cohort investigation to assess whether donepezil usage affects cardiovascular mortality. In patients treated with donepezil, hazard ratios for total and cardiovascular mortality were 0.68 (P = 0.045, 95% confidence interval 0.46-0.99) and 0.54 (P = 0.042, 95% confidence interval 0.30-0.98), respectively. The apparent survival benefit in donepezil-treated patients should not be overinterpreted. Prospective clinical trials are warranted.

    PMID:
    20664535
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3120840
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1

      Supplemental Content

      Icon for Nature Publishing Group Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk